BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24189439)

  • 1. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1.
    Wang Y; Qu Y; Zhang XL; Xing J; Niu XL; Chen X; Li ZM
    Mol Cell Endocrinol; 2014 Feb; 382(2):791-803. PubMed ID: 24189439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL6 induces TAM resistance via kinase-specific phosphorylation of ERα in OVCA cells.
    Wang Y; Niu XL; Guo XQ; Yang J; Li L; Qu Y; Xiu Hu C; Mao LQ; Wang D
    J Mol Endocrinol; 2015 Jun; 54(3):351-61. PubMed ID: 25943392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells.
    Torres-López L; Maycotte P; Liñán-Rico A; Liñán-Rico L; Donis-Maturano L; Delgado-Enciso I; Meza-Robles C; Vásquez-Jiménez C; Hernández-Cruz A; Dobrovinskaya O
    J Leukoc Biol; 2019 May; 105(5):983-998. PubMed ID: 30645008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
    Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
    Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
    Nowak-Markwitz E; Maciejczyk A; Pudełko M; Tserenchunt G; Balázs G; Spaczyński M; Zabel M; Dietel M; Lage H; Surowiak P
    Ginekol Pol; 2010 Mar; 81(3):183-7. PubMed ID: 20486538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer.
    Yang J; Wang Y; Gao Y; Shao J; Zhang XJ; Yao Z
    Cytokine; 2009 Jun; 46(3):382-91. PubMed ID: 19401270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
    Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
    Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine interferon-γ may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor β subtype.
    Niu XL; Wang Y; Yao Z; Duan H; Li Z; Liu W; Zhang H; Deng WM
    Oncol Rep; 2015 Dec; 34(6):3120-30. PubMed ID: 26397740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation].
    Wang Y; Guo XQ; Niu XL; Wu J; Zhu YQ; Mao LQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jan; 26(1):21-4. PubMed ID: 20056081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.